华中科技大学同济医学院附属协和医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 鼻咽癌Nasopharyngeal carcinoma11 篇牵头论文牵头 1 项开放试验
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma8 篇牵头论文牵头 1 项开放试验
- 肝细胞癌Hepatocellular carcinoma144 篇牵头论文牵头 6 项开放试验
- 胃癌Stomach cancer78 篇牵头论文牵头 9 项开放试验
- 肝母细胞瘤Hepatoblastoma1 篇牵头论文
- 视网膜母细胞瘤Retinoblastoma2 篇牵头论文
- 脊索瘤Chordoma1 篇牵头论文
- 骨肉瘤Osteosarcoma25 篇牵头论文
- 胃肠道间质瘤Gastrointestinal stromal tumour18 篇牵头论文
- 神经母细胞瘤Neuroblastoma8 篇牵头论文
- 尤文肉瘤Ewing sarcoma2 篇牵头论文
- 多发性骨髓瘤Multiple myeloma30 篇牵头论文牵头 5 项开放试验
- B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia3 篇牵头论文牵头 2 项开放试验
- 再生障碍性贫血Aplastic anaemia2 篇牵头论文牵头 1 项开放试验
- 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis8 篇牵头论文
- 血友病 AHaemophilia A1 篇牵头论文
- 范可尼贫血Fanconi anaemia1 篇牵头论文
- 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder1 篇牵头论文
- IgG4相关性疾病IgG4-related disease0 篇牵头论文
- 重症肌无力Myasthenia gravis0 篇牵头论文牵头 1 项开放试验
- 烟雾病Moyamoya disease2 篇牵头论文
- 胆道闭锁Biliary atresia7 篇牵头论文
- 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis2 篇牵头论文
- 大动脉炎Takayasu arteritis1 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis3 篇牵头论文
- 肌萎缩侧索硬化症Amyotrophic lateral sclerosis0 篇牵头论文
- 白塞病Behçet disease0 篇牵头论文
- IgA 肾病IgA nephropathy2 篇牵头论文牵头 1 项开放试验
- 成骨不全症Osteogenesis imperfecta1 篇牵头论文
- 原发性胆汁性胆管炎Primary biliary cholangitis3 篇牵头论文
- 原发性硬化性胆管炎Primary sclerosing cholangitis0 篇牵头论文
- 先天性膈疝Congenital diaphragmatic hernia1 篇牵头论文
- 先天性巨结肠Hirschsprung disease8 篇牵头论文
- 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文
未列出的收录疾病:β 地中海贫血、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、肝豆状核变性、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、Alport 综合征、戈谢病、尼曼-匹克病 C 型、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
鼻咽癌
Nasopharyngeal carcinoma2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 11 篇,占 0.5%。
武汉有 6 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下
这家医院参与的开放试验 8
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma
- 分期
- III期
- 开始
- 2025-09
- 登记号
- NCT07177443
年龄 18 岁 至 65 岁(登记的条件)
牵头:华中科技大学同济医学院附属协和医院武汉
- 正在招募Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma
- 分期
- II期
- 开始
- 2026-07
- 登记号
- NCT07528183
年龄 18 岁 至 70 岁(登记的条件)
牵头:中山大学肿瘤防治中心;另有 3 家列出的医院为研究中心南宁、广州、武汉、福州
- 正在招募QL1706(PD-1/CTLA-4 双特异性抗体)联合放化疗用于局部区域晚期鼻咽癌QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
- 分期
- III期
- 开始
- 2025-05
- 登记号
- NCT06749899
年龄 18 岁 至 65 岁(登记的条件)
牵头:中山大学肿瘤防治中心;另有 17 家列出的医院为研究中心上海、东莞、中山、佛山、南京、南宁、厦门、天津、广州、成都、武汉、福州、贵阳、长沙
- 正在招募A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
- 分期
- II期
- 开始
- 2025-04
- 登记号
- NCT06839066
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 14 家列出的医院为研究中心东莞、中山、南宁、广州、成都、杭州、武汉、深圳、福州、赣州、长沙
- 正在招募A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
- 分期
- II期
- 开始
- 2024-01
- 登记号
- NCT05956587
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 14 家列出的医院为研究中心临沂、南昌、天津、广州、杭州、柳州、武汉、福州、西安、郑州、重庆
- 正在招募Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
- 分期
- III期
- 开始
- 2024-03
- 登记号
- NCT06239727
年龄 18 岁 至 65 岁(登记的条件)
牵头:中山大学肿瘤防治中心;另有 21 家列出的医院为研究中心东莞、佛山、南京、南宁、南昌、厦门、天津、广州、成都、杭州、武汉、汕头、海口、湛江、福州、西安、贵阳、重庆、长沙
- 正在招募TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
- 分期
- II期
- 开始
- 2024-03
- 登记号
- NCT06301165
年龄 18 岁 至 65 岁(登记的条件)
牵头方不是列出的医院;另有 8 家列出的医院为研究中心东莞、佛山、广州、武汉、深圳
- 正在招募A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
- 分期
- I期
- 开始
- 2021-11
- 登记号
- NCT05194982
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 6 家列出的医院为研究中心广州、武汉、重庆、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。卡片标题如有中文,为 AI 生成的译文,英文原文附后。
这些数字背后的记录
牵头的论文11
- Deubiquitinase USP7 stabilizes KDM5B and promotes tumor progression and cisplatin resistance in nasopharyngeal carcinoma through the ZBTB16/TOP2A axis.
- Nomograms incorporating primary tumor response at mid-radiotherapy to predict survival in locoregionally advanced nasopharyngeal carcinoma.
- Down-regulated lncRNA ROR in tumor-educated platelets as a liquid-biopsy biomarker for nasopharyngeal carcinoma.
- Tumor factors associated with in-field failure for nasopharyngeal carcinoma after intensity-modulated radiotherapy.
- Prognostic and clinicopathological significance of lymphocyte-to-monocyte ratio in patients with nasopharyngeal carcinoma.
- Molecular characteristics of pediatric nasopharyngeal carcinoma using whole-exome sequencing.
- Adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Finding the suitable population.
- A Bayesian network meta-analysis of the primary definitive therapies for locoregionally advanced nasopharyngeal carcinoma: IC+CCRT, CCRT+AC, and CCRT alone.
- Prognostic value of pretreatment prognostic nutritional index and lactated dehydrogenase in locally advanced nasopharyngeal carcinoma patients.
- Long-term Therapeutic Outcome and Prognostic Factors of Patients with Nasopharyngeal Carcinoma Receiving Intensity-modulated Radiotherapy: An Analysis of 608 Patients from Low-endemic Regions of China.
- A head-to-head comparison of 68Ga-DOTA-FAPI-04 and 18F-FDG PET/MR in patients with nasopharyngeal carcinoma: a prospective study.
它在 ClinicalTrials.gov 上的全部试验(任何状态)24
- Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma
- Pembrolizumab + MRGOO3 as Neoadjuvant in NPC
- The Clinical Application Value of CAIX-Targeted PET Hypoxia Imaging in Malignant Tumors
- Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma
- Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma
- QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
- A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
- Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
- A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
- TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
- A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
- A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
- Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)
- Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma
- TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
- PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma
- Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma
- Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)
- PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
- The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer
- Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
- Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma
- Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer
PubMed 以外找到的论文(未计入)34
- 1371P Nivolumab plus chemoradiotherapy sparing concurrent cisplatin in nasopharyngeal carcinoma (NPC): Social reintegration and patient-reported outcomes (PROs) in quality-of-life (QoL) and tolerability from a phase II PLATINUM trial
- 669MO Long term overall survival follow-up of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma
- Becotatug vedotin vs. chemotherapy in pre-heavily treated advanced nasopharyngeal carcinoma: A randomized, controlled, multicenter, open-label study.
- Combination of Tim-3 blockade TQB2618 with penpulimab and chemotherapy in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): A multicenter, single-arm, two-cohort, phase 2 study.
- DoseNet: Dose-adaptive prediction of the parotid glands deformation for radiotherapy planning
- Expert-Constrained Deep Learning Framework for Nasopharyngeal Carcinoma Automated Target Delineation
- PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized
- Unsupervised deep learning model for fast energy layer pre-selection of delivery-efficient proton arc therapy plan optimization of nasopharyngeal carcinoma
- 416P A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with chemotherapy for the treatment of anti-PD-1 resistant, recurrent, or metastatic nasopharyngeal carcinoma (R/M NPC)
- Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.
- Analysis of proliferating Treg cells as a predictor for immunotherapy response using systemic longitudinal immune profiling: Biomarker analysis of the phase 3 CONTINUUM trial.
- Anatomical and Dosimetric Variations during VMAT in Patients with Locally Advanced Nasopharyngeal Carcinoma after Induction Therapy: Implications for Adaptive Radiation Therapy
- Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study.
- Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).
- Induction chemotherapy followed by concurrent chemoradiotherapy combined with toripalimab and Endostar in high-risk locally advanced nasopharyngeal carcinoma: A multicenter, randomized, phase 2 trial.
- Long-term outcomes of anlotinib and penpulimab combined with chemotherapy in the treatment of patients with metastatic nasopharyngeal carcinoma that failed definitive platinum-based chemoradiotherapy.
- Nivolumab combined with chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): A multicenter, single-arm, phase II clinical trial.
- Nivolumab combined with radical chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): An investigator-initiated, open-label, multicenter, single-arm, phase II clinical trial
- PD-1 blockade with camrelizumab after chemoradiotherapy in nasopharyngeal carcinoma.
- Radiotherapy alone vs radiotherapy with concurrent chemoradiotherapy in patients with low-risk nasopharyngeal carcinoma: Updated results from a multicenter, open-label, non-inferiority, randomized phase III trial.
- A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors.
- A phase Ib/II study of GFH018 in combination with toripalimab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).
- CACA guidelines for holistic integrative management of nasopharyngeal carcinoma
- Camrelizumab plus taxanes and cisplatin (TP) chemotherapy or TP chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma
- Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
- Long-term outcomes of nasopharyngeal carcinoma by Epstein-Barr virus status in the Chinese population: a multicenter investigation
- PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM)
- Standard Therapy vs. Individualized Therapy in Elderly Locally Advanced Nasopharyngeal Carcinoma: A Real-World Study
- Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal ca
- Long-term outcomes of nasopharyngeal carcinoma by Epstein-Barr virus status in the Chinese population: a multicenter investigation
- Penpulimab plus gemcitabine in combination with cisplatin or anlotinib as first-line treatment for metastatic nasopharyngeal carcinoma (M NPC): A phase II study.
- AccuLearning: A User-Friendly Deep Learning Auto-Segmentation Platform for Radiotherapy
- Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.
- Patterns of Local-Regional Relapse Following Intensity-Modulated Radiotherapy for Patients With Nasopharyngeal Carcinoma
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.3%。
武汉有 5 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 即将招募Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC
- 分期
- II期
- 开始
- 2026-02
- 登记号
- NCT07403435
年龄 18 岁 至 75 岁(登记的条件)
牵头:华中科技大学同济医学院附属协和医院武汉
- 正在招募A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- 分期
- III期
- 开始
- 2025-03
- 登记号
- NCT06644781
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 28 家列出的医院为研究中心临沂、北京、南宁、厦门、合肥、哈尔滨、天津、安阳、成都、扬州、新乡、杭州、武汉、汕头、沈阳、洛阳、济南、济宁、福州、郑州、长春
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文8
- NCF2 drives tumor progression and metastasis through NR2F2/LATS2/YAP1 axis in esophageal squamous cell carcinoma.
- The crossroads of inflammation and nutrition: predicting neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma patients.
- Neoadjuvant chemoradiotherapy plus sequential tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): A single-arm, bicentric, phase 2 trial.
- CT-based delta-radiomics for predicting pathological response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma: a multicenter study.
- Efficacy, safety, and prognostic modeling in neoadjuvant immunotherapy for esophageal squamous cell carcinoma.
- Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): the protocol of a prospective, single-arm, phase II trial.
- Cetuximab enhances radiosensitivity of esophageal squamous cell carcinoma cells by G2/M cycle arrest and DNA repair delay through inhibiting p-EGFR and p-ERK.
- Exploration of an effective training system for diagnosis of superficial esophageal squamous cell carcinoma with magnifying narrow-band imaging: Prospective research.
它在 ClinicalTrials.gov 上的全部试验(任何状态)13
- Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC
- Chemoradiotherapy Plus Immunotherapy Followed by Surgery for Esophageal Cancer
- A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
- Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
- Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
- Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
- A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors
- A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
- A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
- A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
- A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
- Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma
PubMed 以外找到的论文(未计入)12
- 2125P A phase II study of simmitinib in combination with liposomal irinotecan for second-line treatment of advanced esophageal squamous cell carcinoma
- Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis
- Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.
- Neoadjuvant Chemoradiotherapy plus Sequential Tislelizumab Followed by Surgery for Esophageal Carcinoma (CRISEC study): A Prospective, Single-Arm, Phase II Trial
- 145P Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
- Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).
- KC1036, a novel oral multi-kinase inhibitor, in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC): Results from a multicenter, single-arm phase II trial.
- 163P Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma: An interim analysis of the prospective, single-arm, phase II trial
- Additional file 1 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration
- Additional file 2 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration
- Additional file 4 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration
- Additional file 5 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 144 篇,占 1.0%。
武汉有 6 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下
这家医院参与的开放试验 11
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
- 分期
- II期
- 开始
- 2026-10
- 登记号
- NCT07776080
年龄 18 岁 至 75 岁(登记的条件)
牵头:华中科技大学同济医学院附属协和医院武汉
- 正在招募Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)
- 分期
- 未注明
- 开始
- 2025-07
- 登记号
- NCT07059936
年龄 18 岁 至 未注明(登记的条件)
牵头:华中科技大学同济医学院附属协和医院武汉
- 正在招募Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE
- 分期
- 未注明
- 开始
- 2025-11
- 登记号
- NCT07235410
年龄 18 岁 至 未注明(登记的条件)
牵头:华中科技大学同济医学院附属协和医院武汉
- 正在招募HAIC (Hepatic Artery Infusion Chemotherapy,HAIC)Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma
- 分期
- II期
- 开始
- 2024-01
- 登记号
- NCT06244225
年龄 18 岁 至 未注明(登记的条件)
牵头:华中科技大学同济医学院附属协和医院武汉
- 正在招募Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma
- 分期
- 早期I期
- 开始
- 2023-09
- 登记号
- NCT06383520
年龄 18 岁 至 65 岁(登记的条件)
牵头:华中科技大学同济医学院附属协和医院武汉
- 即将招募Head to Head, Prospective, Open Label Multicenter Study on the Diagnostic Efficacy of GPC3 Targeted PET Imaging and Enhanced Magnetic Resonance Imaging for Hepatocellular Carcinoma
- 分期
- 早期I期
- 开始
- 2026-01
- 登记号
- NCT07352345
年龄 18 岁 至 未注明(登记的条件)
牵头:华中科技大学同济医学院附属协和医院武汉
- 正在招募A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
- 分期
- II期
- 开始
- 2025-07
- 登记号
- NCT07052253
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心武汉
- 正在招募Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- 分期
- I期
- 开始
- 2025-11
- 登记号
- NCT07176650
年龄 18 岁 至 65 岁(登记的条件)
牵头方不是列出的医院;另有 27 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、海口、石家庄、福州、蚌埠、西安、郑州、长春
- 正在招募ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- 分期
- II期
- 开始
- 2025-06
- 登记号
- NCT07327034
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙
- 正在招募A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- 分期
- I/II期
- 开始
- 2024-07
- 登记号
- NCT06427941
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 16 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、福州、重庆、长沙
- 即将招募Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
- 分期
- 不分期
- 开始
- 2025-06
- 登记号
- NCT07010588
年龄 18 岁 至 75 岁(登记的条件)
牵头:北京大学人民医院;另有 8 家列出的医院为研究中心北京、哈尔滨、武汉、济南、西安、重庆、长春、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文144
- Recent Advances in Embolic Agents for Transarterial Chemoembolization of Hepatocellular Carcinoma.
- Hyaluronidase optimizes TACE in hepatocellular carcinoma by remodeling tumor stroma and enhancing chemotherapy penetration.
- Development and validation of a score model for predicting the risk of first esophagogastric variceal hemorrhage and mortality in patients with hepatocellular carcinoma.
- RALOX-HAIC (raltitrexed + oxaliplatin) combined with lenvatinib improves survival and safety in elderly patients with unresectable hepatocellular carcinoma.
- Efficacy and safety analysis of D-TACE combined with lenvatinib in the treatment of hepatocellular carcinoma refractory to C-TACE.
- Long-term efficacy of transarterial chemoembolization in the treatment of recurrent hepatocellular carcinoma.
- Feasibility, efficacy, and safety of ventral caudal artery access for transarterial chemoembolization in a rat hepatocellular carcinoma model.
- Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial.
- Ellagic acid mediated pyroptosis in hepatocellular carcinoma via the ESR1/G6PD pathway.
- Oncolytic peptide LTX-315 plus an anti-CTLA-4 antibody induces a synergistic anti-cancer immune response in residual tumors after radiofrequency ablation of hepatocellular carcinoma.
- STAT3 orchestrates immune dynamics in hepatocellular carcinoma: A pivotal nexus in tumor progression.
- Hepatic Artery Infusion Chemotherapy for Hepatocellular Carcinoma: Clinical Advancements.
- [68Ga]Ga-PSMA-617 PET/MRI for imaging patients suspected of hepatocellular carcinoma.
- Immunotherapy improved the efficacy of TACE or TACE plus MTTs in HCC patients: A meta-analysis.
- The Dual Role of TRADD in Liver Disease: From Cell Death Regulation to Inflammatory Microenvironment Remodeling.
- Exosome-Delivered circFOXP1 Upregulates Autophagy and Promotes Hepatocellular Carcinoma Progression Through Its Encoded p196 Protein Targeting the KHDRBS3/ULK1 Axis.
- Protein Induced by Vitamin K Absence or Antagonist-II: Significantly Elevated in Obstructive Jaundice and Sepsis Patients Without Hepatocellular Carcinoma.
- COX-2/PGE2 axis blockade with celecoxib enhances anti-PD-1 efficacy by activating natural killer cells for residual hepatocellular carcinoma after radiofrequency ablation.
- Stereotactic body radiotherapy with sintilimab and bevacizumab biosimilar in anti-PD-1 refractory hepatocellular carcinoma: the ReUNION-1 phase 2 trial.
- A glucose kinase-independent HK2 activity prevents TNF-induced cell death by phosphorylating RIPK1.
- [Expression of Concern] Reciprocal negative feedback loop between EZH2 and miR‑101‑1 contributes to miR‑101 deregulation in hepatocellular carcinoma.
- The efficacy and safety analysis of D-TACE combined with donafenib and tislelizumab in recurrent hepatocellular carcinoma after surgery.
- Prognostic impact of extracellular volume fraction derived from equilibrium contrast-enhanced CT in HCC patients receiving immune checkpoint inhibitors.
- Comparative efficacy and safety of transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors versus tyrosine kinase inhibitors and immune checkpoint inhibitors alone in advanced hepatocellular
- Efficacy Analysis of PTCD + TACE vs PTCD + Apatinib in the Treatment of HCC with Obstructive Jaundice: A Retrospective Study.
- Construction of a random survival forest model based on a machine learning algorithm to predict early recurrence after hepatectomy for adult hepatocellular carcinoma.
- Comparative analysis of efficacy and safety between D-TACE + HAIC + lenvatinib and D-TACE + lenvatinib in the treatment of unresectable massive hepatocellular carcinoma.
- Predictors and risk factors of bile duct injury after transcatheter arterial chemoembolization for hepatocellular carcinoma.
- Nomograms established for predicting microvascular invasion and early recurrence in patients with small hepatocellular carcinoma.
- Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor.
- Embolization alone is as effective as TACE for unresectable HCC: systematic review and meta-analysis of randomized controlled trails.
- Efficacy and safety of SBRT combined with sintilimab and IBI305 in patients with advanced HCC and previously failed immunotherapy: study protocol of a phase 2 clinical trial.
- Recent advances in hepatocellular carcinoma-targeted nanoparticles.
- Parapharyngeal and maxillary metastasis in hepatocellular carcinoma as the first presentation: a rare case.
- Efficacy and Safety of TACE Combined with Regorafenib versus TACE Combined with Camrelizumab in Hepatocellular Carcinoma With Untreatable Progression After TACE Combined with Sorafenib Therapy: A Case Control Study.
- Deciphering the immunological and prognostic features of hepatocellular carcinoma through ADP-ribosylation-related genes analysis and identify potential therapeutic target ARFIP2.
- Cell Cycle-Related LncRNA-Based Prognostic Model for Hepatocellular Carcinoma: Integrating Immune Microenvironment and Treatment Response.
- Incidence, Risk Factors, and Prognosis of Patients with Hepatocellular Carcinoma and Brain Metastases.
- TRAF2 decrease promotes the TGF-β-mTORC1 signal in MAFLD-HCC through enhancing AXIN1-mediated Smad7 degradation.
- Hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and molecular targeted therapies for advanced infiltrative hepatocellular carcinoma: a single-center experience.
- Progressive sarcopenia and myosteatosis predict prognosis of advanced HCC patients treated with immune checkpoint inhibitors.
- IL-22 signaling promotes sorafenib resistance in hepatocellular carcinoma via STAT3/CD155 signaling axis.
- Blocking TGFβR synergistically enhances anti-tumor effects of anti-PD-1 antibody in a mouse model of incomplete thermal ablation.
- Radiofrequency hyperthermia enhances the effect of OK-432 for Hepatocellular carcinoma by activating of TLR4-cGAS-STING pathway.
- Exosomal SLC16A1-AS1-induced M2 macrophages polarization facilitates hepatocellular carcinoma progression.
- The m6A modification-mediated positive feedback between glycolytic lncRNA SLC2A1-DT and c-Myc promotes tumorigenesis of hepatocellular carcinoma.
- Drug-Loaded Tumor-Derived Microparticles Elicit CD8+ T Cell-Mediated Anti-Tumor Response in Hepatocellular Carcinoma.
- Synergistic Effects of Nanoscale CaO2 Combined with PD-1 Inhibitors in the Treatment of Hepatocellular Carcinoma: A Promising Combination.
- Relaxin combined with transarterial chemoembolization achieved synergistic effects and inhibited liver cancer metastasis in a rabbit VX2 model.
- Multi-Omics Profiling and Experimental Verification of Lysosomes-Related Genes in Hepatocellular Carcinoma.
- The liquid-liquid phase separation signature predicts the prognosis and immunotherapy response in hepatocellular carcinoma.
- Enhanced efficacy of combined VEGFR peptide-drug conjugate and anti-PD-1 antibody in treating hepatocellular carcinoma.
- Prognosis and chemotherapy drug sensitivity in liver hepatocellular carcinoma through a disulfidptosis-related lncRNA signature.
- Ablation alone is noninferior to radiotherapy plus ablation in the patients with early-stage hepatocellular carcinoma: a population-based study.
- Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies.
- Drug-eluting bead transarterial chemoembolization combined with apatinib/camrelizumab for the treatment of advanced hepatocellular carcinoma with hepatic arterioportal shunts.
- Sorafenib plus transcatheter arterial chemoembolization with or without camrelizumab for the treatment of intermediate and advanced hepatocellular carcinoma.
- Decreased lncRNA HNF4A-AS1 facilitates resistance to sorafenib-induced ferroptosis of hepatocellular carcinoma by reprogramming lipid metabolism.
- Comparison of laparoscopic hepatectomy and radiofrequency ablation for small hepatocellular carcinoma patients: a SEER population-based propensity score matching study.
- Ferroptosis-Enhanced Immunotherapy with an Injectable Dextran-Chitosan Hydrogel for the Treatment of Malignant Ascites in Hepatocellular Carcinoma.
- Efficacy and Safety of Lobaplatin-TACE in the Treatment of Primary Hepatocellular Carcinoma: A Retrospective Study.
- A rare case of hepatocellular carcinoma supplied by the left internal mammary artery treated with transarterial chemoembolization.
- Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study.
- Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study.
- TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma.
- Nuclear respiratory factor 1 drives hepatocellular carcinoma progression by activating LPCAT1-ERK1/2-CREB axis.
- Synergistic effect of OK-432 in combination with an anti-PD-1 antibody for residual tumors after radiofrequency ablation of hepatocellular carcinoma.
- Shp2 Deficiency in Kupffer Cells and Hepatocytes Aggravates Hepatocarcinogenesis by Recruiting Non-Kupffer Macrophages.
- Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
- Safety and Effectiveness of Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Aged Greater versus Less Than 80 Years.
- Transarterial chemoembolization failure in patients with hepatocellular carcinoma: Incidence, manifestation and risk factors.
- Comprehensive Treatment Uncertainty Analysis and PTV Margin Estimation for Fiducial Tracking in Robotic Liver Stereotactic Body Radiation Therapy.
- Liver Transplantation Outcomes of HBV-, HCV-, and Alcohol-induced Hepatocellular Carcinoma in the United States: Analysis of National Inpatient Samples.
- Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma.
- Study on anxiety and depression in elderly patients with malignant liver tumor undergoing hepatectomy.
- Validation and utility of HepG2 xenograft model for hepatocellular carcinoma.
- [177Lu]Lu-PSMA-617 theranostic probe for hepatocellular carcinoma imaging and therapy.
- A gadoxetic-acid enhancement flux analysis of small liver nodules (≤2 cm) in patients at high risk of hepatocellular carcinoma.
- Contrast-enhanced CT parameters predict short-term tumor response in patients with hepatocellular carcinoma who received sequential combined anti-angiogenesis and immune checkpoint inhibitor treatment.
- A novel liver zonation phenotype-associated molecular classification of hepatocellular carcinoma.
- Radiation therapy in the era of immune treatment for hepatocellular carcinoma.
- Diabetes and the risk of cirrhosis and HCC: An analysis of the UK Biobank.
- Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma.
- FARSB Facilitates Hepatocellular Carcinoma Progression by Activating the mTORC1 Signaling Pathway.
- Deficiency of Carbamoyl Phosphate Synthetase 1 Engenders Radioresistance in Hepatocellular Carcinoma via Deubiquitinating c-Myc.
- LncRNA FTO-IT1 promotes glycolysis and progression of hepatocellular carcinoma through modulating FTO-mediated N6-methyladenosine modification on GLUT1 and PKM2.
- Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation.
- Efficacy, mechanism, and safety of melatonin-loaded on thermosensitive nanogels for rabbit VX2 tumor embolization: A novel design.
- Machine learning methods for accurately predicting survival and guiding treatment in stage I and II hepatocellular carcinoma.
- Efficacy and safety analysis of dexamethasone + palonosetron in prevention of post-embolization syndrome after D-TACE: A retrospective study.
- Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles.
- A novel fatty acid metabolism-related gene prognostic signature and candidate drugs for patients with hepatocellular carcinoma.
- Association between sarcopenia and clinical outcomes in patients with hepatocellular carcinoma: an updated meta-analysis.
- Pyogenic liver abscess in non-liver cancer patients and liver cancer patients treated with TACE: Etiological characteristics, treatment, and outcome analysis.
- The role of gadoxetic acid-enhanced MRI features for predicting microvascular invasion in patients with hepatocellular carcinoma.
- The safety and efficacy of percutaneous ethanol injection in the treatment of tumor thrombus in advanced hepatocellular carcinoma with portal vein tumor thrombus.
- Nanoscale CaO2 materials for synergistic transarterial chemoembolization in a VX2 orthotopic rabbit liver cancer model.
- Ferroptosis-related long non-coding RNA signature predicts the prognosis of hepatocellular carcinoma.
- Renal and hepatic artery embolization with Pickering gel emulsion of lipiodol in rabbit.
- MYBL2 regulates de novo purine synthesis by transcriptionally activating IMPDH1 in hepatocellular carcinoma cells.
- Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
- Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma.
- Circ_0000591 served as endogenous RNA for miR-326 to promote progression of cholangiocarcinoma via the TLR4/MyD88/IL6 axis.
- Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.
- Arterial enhancement fraction in evaluating the therapeutic effect and survival for hepatocellular carcinoma patients treated with DEB-TACE.
- Comparison of the Efficacy Among Transcatheter Arterial Chemoembolization (TACE)-Radiofrequency Ablation Plus Apatinib, TACE Plus Apatinib, and TACE Alone for Hepatocellular Carcinoma: A Retrospective Study.
- S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway.
- Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
- Transarterial Chemoembolization Combined with Apatinib for Treatment of Advanced Hepatocellular Carcinoma: Analysis of Survival and Prognostic Factors.
- Application of Intravoxel Incoherent Motion in the Evaluation of Hepatocellular Carcinoma after Transarterial Chemoembolization.
- Perioperative factors related to the prognosis of elderly patients with hepatocellular carcinoma.
- PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [68Ga]Ga-PSMA-617.
- Identification of a novel histone phosphorylation prognostic signature in hepatocellular carcinoma based on bulk and single-cell RNA sequencing.
- Molecular Imaging of Tumor Microenvironment to Assess the Effects of Locoregional Treatment for Hepatocellular Carcinoma.
- The impact of particulate matter 2.5 on the risk of hepatocellular carcinoma: a meta-analysis.
- Microwave ablation combined with anti-PD-1 therapy enhances systemic antitumor immunity in a multitumor murine model of Hepa1-6.
- Association of Adjuvant Radiation Therapy With Long-Term Overall and Recurrence-Free Survival After Hepatectomy for Hepatocellular Carcinoma: A Multicenter Propensity-Matched Study.
- Enhanced efficacy of direct immunochemotherapy for hepatic cancer with image-guided intratumoral radiofrequency hyperthermia.
- Research Progress in Alpha-fetoprotein-induced Immunosuppression of Liver Cancer.
- Multimodal Imaging Response after the Singular or Combination Treatments of Vascular Endothelial Growth Factor Inhibitor and Immune Checkpoint Inhibitor.
- The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus.
- Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression.
- Liver abscess after drug-eluting bead chemoembolization in patients with metastatic hepatic tumors.
- Crosstalk between macrophage-derived PGE2 and tumor UHRF1 drives hepatocellular carcinoma progression.
- Effect of perioperative factors on the prognosis of patients with hepatocellular carcinoma who underwent hepatectomy.
- Mechanism and risk factors of nausea and vomiting after TACE: a retrospective analysis.
- Integrated analysis of the functions and prognostic values of RNA binding proteins in hepatocellular carcinoma.
- Efficacy and safety analysis of dexamethasone-lipiodol emulsion in prevention of post-embolization syndrome after TACE: a retrospective analysis.
- Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study.
- Development of a novel lipid metabolism-based risk score model in hepatocellular carcinoma patients.
- MicroRNA miR-495 regulates the development of Hepatocellular Carcinoma by targeting C1q/tumor necrosis factor-related protein-3 (CTRP3).
- Sublethal hyperthermia enhances anticancer activity of doxorubicin in chronically hypoxic HepG2 cells through ROS-dependent mechanism.
- The efficacy of radiofrequency ablation versus cryoablation in the treatment of single hepatocellular carcinoma: A population-based study.
- Epigenetic and Immune-Cell Infiltration Changes in the Tumor Microenvironment in Hepatocellular Carcinoma.
- Efficacy of apatinib in patients with sorafenib-transarterial chemoembolization refractory hepatocellular carcinoma: a retrospective study.
- Transcatheter chemoembolization plus percutaneous radiofrequency ablation versus laparoscopic radiofrequency ablation: improved outcome for inoperable hepatocellular carcinoma.
- Single sample scoring of hepatocellular carcinoma: A study based on data mining.
- Radiomics Signature: A potential biomarker for the prediction of survival in Advanced Hepatocellular Carcinoma.
- Downregulation of hsa_circ_0074854 Suppresses the Migration and Invasion in Hepatocellular Carcinoma via Interacting with HuR and via Suppressing Exosomes-Mediated Macrophage M2 Polarization.
- Lenvatinib and Cu2-xS nanocrystals co-encapsulated in poly(D,L-lactide-co-glycolide) for synergistic chemo-photothermal therapy against advanced hepatocellular carcinoma.
- Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma.
- Systemic immune-inflammation index predicts postoperative acute kidney injury in hepatocellular carcinoma patients after hepatectomy.
- Value of gadoxetic acid-enhanced MR imaging and DWI in classification, characterization and confidence in diagnosis of solid focal liver lesions.
- Quantitative dual-energy CT for evaluating hepatocellular carcinoma after transarterial chemoembolization.
它在 ClinicalTrials.gov 上的全部试验(任何状态)25
- Head to Head, Prospective, Open Label Multicenter Study on the Diagnostic Efficacy of GPC3 Targeted PET Imaging and Enhanced Magnetic Resonance Imaging for Hepatocellular Carcinoma
- Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
- Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE
- Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)
- HAIC (Hepatic Artery Infusion Chemotherapy,HAIC)Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma
- Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma
- Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma
- Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular Carcinoma
- The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study
- ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
- A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
- Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
- A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
- Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)
- A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
- A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
- Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
- A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
- Study of BGB-A317 in Participants With Previously Treated Unresectable HCC
- Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation
- A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 78 篇,占 0.8%。
武汉有 5 家医院列在胃癌下全国有 218 家医院列在胃癌下
这家医院参与的开放试验 15
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募CT Imaging and Clinical Features to Predict Outcomes in Patients With Gastric Cancer
- 分期
- 未注明
- 开始
- 2026-04
- 登记号
- NCT07776067
年龄 18 岁 至 未注明(登记的条件)
牵头:华中科技大学同济医学院附属协和医院武汉
- 正在招募A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis
- 分期
- II期
- 开始
- 2025-02
- 登记号
- NCT06685887
年龄 18 岁 至 75 岁(登记的条件)
牵头:华中科技大学同济医学院附属协和医院武汉
- 正在招募Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors
- 分期
- 未注明
- 开始
- 2025-09
- 登记号
- NCT07301814
年龄 18 岁 至 未注明(登记的条件)
牵头:华中科技大学同济医学院附属协和医院武汉
- 正在招募Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
- 分期
- II期
- 开始
- 2025-07
- 登记号
- NCT07920224
年龄 18 岁 至 75 岁(登记的条件)
牵头:华中科技大学同济医学院附属协和医院武汉
- 正在招募Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer
- 分期
- II期
- 开始
- 2024-05
- 登记号
- NCT06487429
年龄 18 岁 至 75 岁(登记的条件)
牵头:华中科技大学同济医学院附属协和医院武汉
- 正在招募Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer
- 分期
- II期
- 开始
- 2024-11
- 登记号
- NCT06826079
年龄 18 岁 至 70 岁(登记的条件)
牵头:华中科技大学同济医学院附属协和医院武汉
- 即将招募Exploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Cohort Study
- 分期
- II期
- 开始
- 2026-09
- 登记号
- NCT07872696
年龄 18 岁 至 75 岁(登记的条件)
牵头:华中科技大学同济医学院附属协和医院武汉
- 即将招募Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors
- 分期
- 不分期
- 开始
- 2025-10
- 登记号
- NCT07172503
年龄 18 岁 至 70 岁(登记的条件)
牵头:华中科技大学同济医学院附属协和医院武汉
- 即将招募Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients
- 分期
- IV期
- 开始
- 2024-07
- 登记号
- NCT05498766
年龄 18 岁 至 75 岁(登记的条件)
牵头:华中科技大学同济医学院附属协和医院;另有 1 家列出的医院为研究中心武汉、青岛
- 正在招募Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- 分期
- III期
- 开始
- 2026-04
- 登记号
- NCT07385703
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛
- 正在招募Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
- 分期
- 不分期
- 开始
- 2026-06
- 登记号
- NCT07552402
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南宁、成都、杭州、武汉、石家庄、福州、苏州、银川
- 正在招募A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- 分期
- I期
- 开始
- 2025-07
- 登记号
- NCT07066657
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、北京、哈尔滨、杭州、武汉、郑州、重庆、长沙
- 正在招募A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- 分期
- I/II期
- 开始
- 2024-07
- 登记号
- NCT06427941
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 15 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、重庆、长沙
- 正在招募A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- 分期
- I/II期
- 开始
- 2022-01
- 登记号
- NCT05150691
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、北京、南宁、厦门、合肥、天津、安阳、广州、徐州、无锡、杭州、武汉、沈阳、济南、温州、烟台、石家庄、蚌埠、西安、郑州、重庆、长春、长沙
- 正在招募A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- 分期
- I期
- 开始
- 2022-06
- 登记号
- NCT05365581
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、广州、杭州、武汉、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文78
- Three-Year Follow-Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer-Associated Fibroblast Heterogeneity Corresponding to PD-1 Blockade Efficacy.
- Oxidative Stress Inflammation Score is the Optimal Inflammatory Prognostic Indicator for Patients with Locally Advanced Gastric Cancer Receiving Neoadjuvant Immunochemotherapy: A Multicenter Retrospective Cohort Study.
- Association of different autoimmune diseases with gastric cancer incidence and risk: a global population-based analysis.
- Prognostic value of combined pathological response in primary tumor and lymph nodes after neoadjuvant chemoimmunotherapy for locally advanced gastric cancer.
- Nortriptyline Inhibits Lysosomal Exocytosis-Mediated SASP During Gastric Cancer Progression via Targeting HOXA1-PITX2 Phase Separation.
- Multi-omics analysis reveals disrupted gut microbiota and metabolism in gastric cancer patients with high SIRI.
- Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis.
- Lipid accumulation product and visceral adiposity index as independent predictors of long-term survival after gastric cancer immunotherapy.
- Impact of intraoperative explanation combined with surgical video review on anatomy learning in laparoscopic distal gastrectomy.
- Impaired ARID1A expression attenuated the immune response in gastric cancer via histone acetylation.
- Prognostic value of [68Ga]Ga-FAPI-04 PET in patients with newly diagnosed gastric carcinoma.
- Which surrogate endpoint best predict survival in locally advanced gastric cancer patients undergoing neoadjuvant chemoimmunotherapy followed by surgery? A multicenter retrospective study.
- Establishment of an anaplastic stratification signature for gastric cancer based on diverse regulated cell-death.
- Prognostic value of Naples prognostic score for locally advanced gastric cancer after neoadjuvant chemoimmunotherapy.
- SNORA37/CMTR1/ELAVL1 feedback loop drives gastric cancer progression via facilitating CD44 alternative splicing.
- Effectiveness of Snare Traction-Facilitated Endoscopic Resection for Gastric Submucosal Tumors ≥ 2 cm: A Propensity Score-Matched Study.
- USP29 and SMURF1 orchestrate FSP1-mediated ferroptosis suppression to facilitate chemoresistance in gastric cancer.
- Advancements in non-invasive diagnosis of gastric cancer.
- Preoperative serum magnesium level as a prognostic and predictive biomarker in locally advanced gastric cancer patients receiving neoadjuvant immunochemotherapy.
- ASO Author Reflections: Neoadjuvant Chemotherapy Combined with Immunotherapy is a Promising Strategy for Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.
- Two-Year Outcomes and Biomarker Analysis of Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma After Neoadjuvant Chemotherapy and Immunotherapy from the Phase II WuhanUHGI001 Trial.
- Lymph node ratio is a prognostic indicator for locally advanced gastric cancer after neoadjuvant immunochemotherapy.
- Interleukin-6 on postoperative day three as an early predictor of infections following laparoscopic gastric cancer resection.
- Inhibition of glycolysis enhances the efficacy of immunotherapy via PDK-mediated upregulation of PD-L1.
- Gut Roseburia is a protective marker for peritoneal metastasis of gastric cancer.
- EIF2S2 transcriptionally upregulates HIF1α to promote gastric cancer progression via activating PI3K/AKT/mTOR pathway.
- Gamma-glutamyl transferase secreted by Helicobacter pylori promotes the development of gastric cancer by affecting the energy metabolism and histone methylation status of gastric epithelial cells.
- Human gastric cancer progression and stabilization of ATG2B through RNF5 binding facilitated by autophagy-associated CircDHX8.
- Immune checkpoints signature-based risk stratification for prognosis of patients with gastric cancer.
- Case report metastatic SMARCB1 (INI1)-deficient gastric undifferentiated carcinoma in pleural effusion: A case report and literature review.
- CircMTA2 Drives Gastric Cancer Progression through Suppressing MTA2 Degradation via Interacting with UCHL3.
- A nomogram incorporating treatment data for predicting overall survival in gastroenteropancreatic neuroendocrine tumors: a population-based cohort study.
- Impact of Helicobacter pylori on immunotherapy in gastric cancer.
- The effect of surgery and metastatic risk prediction in patients with gastrointestinal tract signet-ring cell carcinoma.
- Re-analysis of single cell and spatial transcriptomics data reveals B cell landscape in gastric cancer microenvironment and its potential crosstalk with tumor cells for clinical prognosis.
- Prognosis of EBV-positive gastric cancer with lymphoid stroma: systematic review and meta-analysis.
- Helicobacter pylori CagA mediated mitophagy to attenuate the NLRP3 inflammasome activation and enhance the survival of infected cells.
- Analysis of clinicopathological characteristics and prognosis on primary gastric adenosquamous carcinoma.
- Identification of a lipid homeostasis-related gene signature for predicting prognosis, immunity, and chemotherapeutic effect in patients with gastric cancer.
- Tumor size as a significant prognostic factor in T1 gastric cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis.
- Epigenetic and Tumor Microenvironment for Prognosis of Patients with Gastric Cancer.
- Microvesicles from bone marrow-derived mesenchymal stem cells promote Helicobacter pylori-associated gastric cancer progression by transferring thrombospondin-2.
- Prediction of HER2 status via random forest in 3257 Chinese patients with gastric cancer.
- Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort.
- Exosome-Delivered circSTAU2 Inhibits the Progression of Gastric Cancer by Targeting the miR-589/CAPZA1 Axis.
- The impact of surgery and survival prediction in patients with gastroenteropancreatic neuroendocrine tumors: a population-based cohort study.
- circ-hnRNPU inhibits NONO-mediated c-Myc transactivation and mRNA stabilization essential for glycosylation and cancer progression.
- Bone mesenchymal stem cells promote gastric cancer progression through TGF-β1/Smad2 positive feedback loop.
- Clinicopathological characteristics of mixed neuroendocrine-non-neuroendocrine neoplasms in gastrointestinal tract.
- Laparoscopic versus open gastrectomy for locally advanced gastric cancer after neoadjuvant chemotherapy: a comprehensive contrastive analysis with propensity score matching.
- A radiomics model predicts the response of patients with advanced gastric cancer to PD-1 inhibitor treatment.
- Comparative Study of the Efficacy and Safety of Radical Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy in Locally Advanced Gastric Cancer: A Propensity Score-Matching Analysis.
- Therapeutic targeting of the USP2-E2F4 axis inhibits autophagic machinery essential for zinc homeostasis in cancer progression.
- Identification of miRNA biomarkers for stomach adenocarcinoma.
- A dynamic predictive nomogram of long-term survival in primary gastric lymphoma: a retrospective study.
- Effect of Postoperative ω-3 Fatty Acid Immunonutritional Therapy on NK Cell Gene Methylation in Elderly Patients with Gastric Cancer.
- Long noncoding RNA SNHG8 promotes chemoresistance in gastric cancer via binding with hnRNPA1 and stabilizing TROY expression.
- A new therapy for refractory gastric cancer bleeding: endoscopic ultrasound-guided lauromacrogol injection.
- The risk of aspirin induced postoperative hemorrhage: a systematic review and meta-analysis.
- LRG1 mediated by ATF3 promotes growth and angiogenesis of gastric cancer by regulating the SRC/STAT3/VEGFA pathway.
- Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma-rationale for targeting ARID1A deficiency.
- Gamma-glutamyltransferase of Helicobacter pylori alters the proliferation, migration, and pluripotency of mesenchymal stem cells by affecting metabolism and methylation status.
- 68Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with 18F-FDG PET/CT.
- Efficacy of local hemostatic agents after endoscopic submucosal dissection: a meta-analysis.
- Safety and feasibility of laparoscopy-assisted surgery for gastrointestinal stromal tumors larger than 5 cm: Results of a retrospective, single-center series of 1,802 consecutive patients.
- Lymph node ratio is a prospective prognostic indicator for locally advanced gastric cancer patients after neoadjuvant chemotherapy.
- THBS4/integrin α2 axis mediates BM-MSCs to promote angiogenesis in gastric cancer associated with chronic Helicobacter pylori infection.
- The New American Joint Committee on Cancer T staging system for stomach: increased complexity without clear improvement in predictive accuracy for endoscopic ultrasound.
- Bone marrow-derived mesenchymal stem cells promote Helicobacter pylori-associated gastric cancer progression by secreting thrombospondin-2.
- A PD-L1 Negative Advanced Gastric Cancer Patient With a Long Response to PD-1 Blockade After Failure of Systematic Treatment: A Case Report.
- CircGSK3B promotes RORA expression and suppresses gastric cancer progression through the prevention of EZH2 trans-inhibition.
- Targeting MUS81 promotes the anticancer effect of WEE1 inhibitor and immune checkpoint blocking combination therapy via activating cGAS/STING signaling in gastric cancer cells.
- The Gamma-glutamyltransferase gene of Helicobacter pylori can promote gastric carcinogenesis by activating Wnt signal pathway through up-regulating TET1.
- The Potential Role of IL1RAP on Tumor Microenvironment-Related Inflammatory Factors in Stomach Adenocarcinoma.
- Procalcitonin as an Early Predictor of Intra-abdominal Infections Following Gastric Cancer Resection.
- PLAGL2 promotes the proliferation and migration of gastric cancer cells via USP37-mediated deubiquitination of Snail1.
- Plexiform angiomyxoid myofibroblastic tumor treated by endoscopic submucosal dissection: A case report and review of the literature.
- Fecal Streptococcus Alteration Is Associated with Gastric Cancer Occurrence and Liver Metastasis.
中文论文(未计入)4
- [Application of totally laparoscopic right thoracic esophagojejunostomy in adenocarcinoma of the esophagogastric junction (AEG) surgery].
- [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].
- [Safety evaluation of hyperthermic intraperitoneal chemotherapy in patients with local advanced gastric cancer after radical resection for prevention of peritoneal metastasis].
- [Pay attention to misdiagnosis and differential diagnosis of gastric gastrointestinal stromal tumor].
它在 ClinicalTrials.gov 上的全部试验(任何状态)48
- Exploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Cohort Study
- CT Imaging and Clinical Features to Predict Outcomes in Patients With Gastric Cancer
- Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors
- Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors
- A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis
- Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
- Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer
- Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients
- Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer
- Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis
- Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma
- Artificial Intelligence System for Assessment of Tumor Risk and Diagnosis and Treatment
- Development and Demonstration of Intelligent Assessment Based on Multi-modal Information Fusion for Tumor Risk and Diagnosis and Treatment
- Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors
- Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy
- Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy
- Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC
- A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy
- Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer
- A Multicenter Clinical Trial on Laparoscopic Gastric Cancer Surgery Compared With Open Surgery
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
- A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
- A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- Development and Testing of a Social Cognitive Theory-based Dietary Behavioral Intervention in Gastric Cancer Survivors
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
- A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis
- A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
- A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer
- Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
- A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
- Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer
- A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer
- Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)
- Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2
- Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma Surgery
- Roux-en-Y vs. Roux-en-Y+ Pouch for D2 Total Gastrectomy
- Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)
- A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
癌症
肝母细胞瘤
Hepatoblastoma2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
武汉有 5 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
癌症
视网膜母细胞瘤
Retinoblastoma2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
武汉有 18 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。
癌症
脊索瘤
Chordoma2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
武汉有 2 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 25 篇,占 1.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
武汉有 31 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文25
- Immune-Modulating Dual-Targeted Nanomaterials for Low-Temperature Photothermal-Photodynamic-Chemodynamic Therapy of Osteosarcoma Targeting Tumor and Endothelial Cells.
- Bioactive nanocomposite hydrogel enhances postoperative immunotherapy and bone reconstruction for osteosarcoma treatment.
- Cancer-associated Fibroblast-like Cells Promote Osteosarcoma Metastasis by Upregulation of Phosphoserine Aminotransferase 1 and Activation of the mTOR/S6K Pathway.
- GBP1-CDK9-STAT3 signaling axis promotes osteosarcoma PD-L1 expression and immune escape.
- KPNA2 promotes osteosarcoma progression by regulating the alternative splicing of DDX3X mediated by YBX1.
- Signaling pathways and targeted therapies in Ewing sarcoma.
- Cyclin L1 participates in Adriamycin resistance and progression of osteosarcoma via PI3K/AKT-mTOR pathway.
- Effects of Doxorubicin, Epirubicin, and Liposomal Doxorubicin (Anthracycline) on cardiac function in patients with osteosarcoma and their influencing factors.
- Single-cell RNA sequencing reveals SERPINE1-expressing CAFs remodelling tumour microenvironment in recurrent osteosarcoma.
- Deciphering chemoresistance in osteosarcoma: Unveiling regulatory mechanisms and function through the lens of noncoding RNA.
- Biomimetic bone-periosteum scaffold for spatiotemporal regulated innervated bone regeneration and therapy of osteosarcoma.
- Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics.
- Network pharmacology-based research on the effect of Scutellaria baicalensis on osteosarcoma and the underlying mechanism.
- 2-Hydroxy-3-methylanthraquinone inhibits homologous recombination repair in osteosarcoma through the MYC-CHK1-RAD51 axis.
- Targeted Delivery of PD-L1-Derived Phosphorylation-Mimicking Peptides by Engineered Biomimetic Nanovesicles to Enhance Osteosarcoma Treatment.
- Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies.
- SGLT2 inhibitor activates the STING/IRF3/IFN-β pathway and induces immune infiltration in osteosarcoma.
- LncCCAT1 interaction protein PKM2 upregulates SREBP2 phosphorylation to promote osteosarcoma tumorigenesis by enhancing the Warburg effect and lipogenesis.
- Engineered exosome as targeted lncRNA MEG3 delivery vehicles for osteosarcoma therapy.
- Integrative analysis of immune-related multi-omics profiles identifies distinct prognosis and tumor microenvironment patterns in osteosarcoma.
- Quercetin encapsulated in folic acid-modified liposomes is therapeutic against osteosarcoma by non-covalent binding to the JH2 domain of JAK2 Via the JAK2-STAT3-PDL1.
- Single-cell transcriptomics reveals the regulative roles of cancer associated fibroblasts in tumor immune microenvironment of recurrent osteosarcoma.
- CircRAB3IP upregulates twist family BHLH transcription factor (TWIST1) to promote osteosarcoma progression by sponging miR-580-3p.
- Association of MTHFR and ABCB1 polymorphisms with MTX-induced mucositis in Chinese paediatric patients with acute lymphoblastic leukaemia, lymphoma or osteosarcoma-A retrospective cohort study.
- Amplification of oxidative stress with lycorine and gold-based nanocomposites for synergistic cascade cancer therapy.
早期论文(2016–2020 年)29
- Delivery of MutT homolog 1 inhibitor by functionalized graphene oxide nanoparticles for enhanced chemo-photodynamic therapy triggers cell death in osteosarcoma.
- Key genes with prognostic values in suppression of osteosarcoma metastasis using comprehensive analysis.
- Surface engineering of nanoparticles with ligands for targeted delivery to osteosarcoma.
- Hsa_circ_0000285 functions as a competitive endogenous RNA to promote osteosarcoma progression by sponging hsa-miRNA-599.
- PTBP1 modulates osteosarcoma chemoresistance to cisplatin by regulating the expression of the copper transporter SLC31A1.
- LncRNA CRNDE is activated by SP1 and promotes osteosarcoma proliferation, invasion, and epithelial-mesenchymal transition via Wnt/β-catenin signaling pathway.
- Dysregulated circRNAs serve as prognostic and diagnostic markers in osteosarcoma by sponging microRNA to regulate the downstream signaling pathway.
- Dioscin inhibits the growth of human osteosarcoma by inducing G2/M-phase arrest, apoptosis, and GSDME-dependent cell death in vitro and in vivo.
- FGD1 promotes tumor progression and regulates tumor immune response in osteosarcoma via inhibiting PTEN activity.
- MiR-19a as a prognostic indicator for cancer patients: a meta-analysis.
- Association between TP53 rs1042522 gene polymorphism and the risk of malignant bone tumors: a meta-analysis.
- Bruceine D inhibits tumor growth and stem cell-like traits of osteosarcoma through inhibition of STAT3 signaling pathway.
- Transcriptional activation of CBFβ by CDK11p110 is necessary to promote osteosarcoma cell proliferation.
- Dynasore suppresses cell proliferation, migration, and invasion and enhances the antitumor capacity of cisplatin via STAT3 pathway in osteosarcoma.
- Integrative analyses of key genes and regulatory elements in fluoride-affected osteosarcoma.
- Prognostic value of prognostic nutritional index and systemic immune-inflammation index in patients with osteosarcoma.
- LncRNA AFAP1-AS1 promotes tumorigenesis and epithelial-mesenchymal transition of osteosarcoma through RhoC/ROCK1/p38MAPK/Twist1 signaling pathway.
- [Drug therapy of high grade osteosarcoma].
- The isolation, structural characterization and anti-osteosarcoma activity of a water soluble polysaccharide from Agrimonia pilosa.
- Reconstruction with constrained scapular prosthesis after total scapulectomy for scapular malignant tumor.
- RhoA/ROCK pathway inhibition by fasudil suppresses the vasculogenic mimicry of U2OS osteosarcoma cells in vitro.
- Triggering of apoptosis in osteosarcoma cells by graphene/single-walled carbon nanotube hybrids via the ROS-mediated mitochondrial pathway.
- In vitro effect of microRNA-107 targeting Dkk-1 by regulation of Wnt/β-catenin signaling pathway in osteosarcoma.
- Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.
- Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.
- p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines.
- Establishment and characterization of a novel osteosarcoma cell line: CHOS.
- Clinical and biological significance of PIM1 kinase in osteosarcoma.
- Long noncoding RNA MALAT1 as a potential therapeutic target in osteosarcoma.
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 18 篇,占 3.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
武汉有 9 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- 分期
- II/III期
- 开始
- 2026-05
- 登记号
- NCT07379047
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、成都、昆明、杭州、武汉、济南、石家庄、福州、贵阳、郑州、重庆、长春、长沙、青岛
- 正在招募A Study of HQP1351 in Patients With GIST or Other Solid Tumors
- 分期
- I期
- 开始
- 2018-07
- 登记号
- NCT03594422
年龄 12 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、北京、广州、武汉、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文18
- Distinguishing very high-risk patients among high-risk gastrointestinal stromal tumor cases: development and validation of a nomogram based on a multicenter population-based retrospective cohort study.
- Imatinib adherence prediction using machine learning approach in patients with gastrointestinal stromal tumor.
- Is lymph node metastasis an advanced event of gastrointestinal stromal tumor?
- Development of a simultaneous quantification method of imatinib and sunitinib and their main metabolites and its application in patients with gastrointestinal stromal tumor.
- Intratumoral microbiome promotes liver metastasis and dampens adjuvant imatinib treatment in gastrointestinal stromal tumor.
- Untargeted metabolomics analysis reveals the potential mechanism of imatinib-induced skin rash in patients with gastrointestinal stromal tumor.
- Ripretinib for the treatment of advanced, imatinib-resistant gastrointestinal stromal tumors.
- Targeting BCL6 in Gastrointestinal Stromal Tumor Promotes p53-Mediated Apoptosis to Enhance the Antitumor Activity of Imatinib.
- Cardiovascular-Specific Mortality among Gastrointestinal Stromal Tumor Patients: A Population-Based Analysis.
- Anaplastic lymphoma kinase expression in PDGFRA-mutated gastrointestinal stromal tumors probably correlates with poor prognosis.
- Clinicopathologic Characteristics and Prognosis of PDGFRA-Mutant Gastrointestinal Stromal Tumors: A Large-Scale, Multi-Institutional, Observational Study in China.
- Laparoscopic Versus Open Surgery for Rectal Gastrointestinal Stromal Tumor: A Multicenter Propensity Score-Matched Analysis.
- Association between preoperative skeletal muscle mass depletion and poor relapse-free survival in patients with gastrointestinal stromal tumors after complete resection.
- Safety and feasibility of laparoscopy-assisted surgery for gastrointestinal stromal tumors larger than 5 cm: Results of a retrospective, single-center series of 1,802 consecutive patients.
- Duodenal gastrointestinal stromal tumors: A retrospective study based on a 13 years experience of a single center in China.
- Radical resection versus local excision for low rectal gastrointestinal stromal tumor: A multicenter propensity score-matched analysis.
- The effect of neoadjuvant imatinib therapy on outcome and survival in rectal gastrointestinal stromal tumors: A multiinstitutional study.
- Efficacy of Endoscopic Ultrasound Elastography in Differential Diagnosis of Gastrointestinal Stromal Tumor Versus Gastrointestinal Leiomyoma.
中文论文(未计入)4
- [Analysis of the efficacy of adjusting the dose of imatinib with therapeutic drug monitoring in adjuvant treatment after complete resection of gastrointestinal stromal tumors].
- [Clinicopathological characteristics and prognosis of patients with sporadic multiple primary gastrointestinal stromal tumors].
- [Adherence to adjuvant with therapy imatinib in patients with gastrointestinal stromal tumor: a national multi-center cross-sectional study].
- [Pay attention to misdiagnosis and differential diagnosis of gastric gastrointestinal stromal tumor].
早期论文(2016–2020 年)17
- Elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis of patients with primary gastrointestinal stromal tumor.
- ALK expressed in a gastrointestinal stromal tumor harboring PDGFRA p. D842V mutation:a case report.
- Development and validation of a prognostic nomogram to predict recurrence in high-risk gastrointestinal stromal tumour: A retrospective analysis of two independent cohorts.
- Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors.
- Laparoscopic Versus Open Surgery for Gastric Gastrointestinal Stromal Tumors: a Propensity Score Matching Analysis.
- Primary Gastrointestinal Stromal Tumor Mimicking as Gynecologic Mass: Characteristics, Management, and Prognosis.
- [Characteristics and targeted therapy of wild-type gastrointestinal stromal tumor].
- [A model to predict the recurrence of middle-high risk gastrointestinal stromal tumors based on preoperative fibrinogen and peripheral blood inflammatory indexes].
- The prognostic value of gastrointestinal bleeding in gastrointestinal stromal tumor: A propensity score matching analysis.
- Adherence to Adjuvant Imatinib Therapy in Patients with Gastrointestinal Stromal Tumor in Clinical Practice: A Cross-Sectional Study.
- A Population-Based Study of the Incidence and Survival of Anorectal Gastrointestinal Stromal Tumor.
- [Laparoscopic versus open surgery for gastric gastrointestinal stromal tumors in unfavorable location: a propensity score-matching analysis].
- [Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].
- Clinicopathological and Prognostic Analysis of Primary Gastrointestinal Stromal Tumor Presenting with Gastrointestinal Bleeding: a 10-Year Retrospective Study.
- Clinicopathologic study of succinate-dehydrogenase-deficient gastrointestinal stromal tumors: A single-institutional experience in China.
- Clinicopathologic features and prognosis of primary gastrointestinal stromal tumor patients under 35 years of age: A 10-year retrospective study.
- [Clinical characteristics and prognosis analysis of 119 cases with giant gastrointestinal stromal tumor].
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
- Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- A Study of HQP1351 in Patients With GIST or Other Solid Tumors
- A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
- A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.7%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
武汉有 11 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文8
- Targeting RBM10-Repressed RORB Activity in Liquid Condensates Inhibits Lysosomal Biogenesis and Neuroblastoma Progression via Affecting NF-κB Signaling.
- Targeting c-Myc transactivation by LMNA inhibits tRNA processing essential for malate-aspartate shuttle and tumour progression.
- YY1 drives PARP1 expression essential for PARylation of NONO in mRNA maturation during neuroblastoma progression.
- Therapeutic targeting of CNBP phase separation inhibits ribosome biogenesis and neuroblastoma progression via modulating SWI/SNF complex activity.
- SIRT3 ameliorates diabetes-associated cognitive dysfunction via regulating mitochondria-associated ER membranes.
- Therapeutic targeting of FUBP3 phase separation by GATA2-AS1 inhibits malate-aspartate shuttle and neuroblastoma progression via modulating SUZ12 activity.
- HNF4A-AS1-encoded small peptide promotes self-renewal and aggressiveness of neuroblastoma stem cells via eEF1A1-repressed SMAD4 transactivation.
- Lead exposure represses mitochondrial metabolism by activation of heme-binding protein BACH1 in differentiated SH-SY5Y cell.
早期论文(2016–2020 年)13
- Long Noncoding RNA NHEG1 Drives β-Catenin Transactivation and Neuroblastoma Progression through Interacting with DDX5.
- Therapeutic targeting of YY1/MZF1 axis by MZF1-uPEP inhibits aerobic glycolysis and neuroblastoma progression.
- SNW1 regulates Notch signaling in neuroblastoma through interacting with RBPJ.
- Valproic acid suppresses Warburg effect and tumor progression in neuroblastoma.
- Therapeutic targeting of circ-CUX1/EWSR1/MAZ axis inhibits glycolysis and neuroblastoma progression.
- Long Noncoding RNA pancEts-1 Promotes Neuroblastoma Progression through hnRNPK-Mediated β-Catenin Stabilization.
- DAPK1-ERK signal mediates oxygen glucose deprivation reperfusion induced apoptosis in mouse N2a cells.
- Armadillo repeat containing 12 promotes neuroblastoma progression through interaction with retinoblastoma binding protein 4.
- Overexpression of Tau Rescues Nogo-66-Induced Neurite Outgrowth Inhibition In Vitro.
- CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
- microRNA-558 facilitates the expression of hypoxia-inducible factor 2 alpha through binding to 5'-untranslated region in neuroblastoma.
- Smad4 suppresses the tumorigenesis and aggressiveness of neuroblastoma through repressing the expression of heparanase.
- Risk stratification and therapeutics of neuroblastoma: the challenges remain.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
癌症
尤文肉瘤
Ewing sarcoma2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
武汉有 6 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。
这些数字背后的记录
牵头的论文2
早期论文(2016–2020 年)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 30 篇,占 1.8%。
武汉有 3 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下
这家医院参与的开放试验 11
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.
- 分期
- 早期I期
- 开始
- 2026-03
- 登记号
- NCT07429721
年龄 18 岁 至 未注明(登记的条件)
牵头:华中科技大学同济医学院附属协和医院武汉
- 正在招募An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
- 分期
- 早期I期
- 开始
- 2025-09
- 登记号
- NCT07101705
年龄 18 岁 至 75 岁(登记的条件)
牵头:华中科技大学同济医学院附属协和医院武汉
- 正在招募The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial
- 分期
- 未注明
- 开始
- 2024-04
- 登记号
- NCT06228794
年龄 18 岁 至 80 岁(登记的条件)
牵头:华中科技大学同济医学院附属协和医院武汉
- 正在招募Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
- 分期
- II期
- 开始
- 2023-10
- 登记号
- NCT06140966
年龄 18 岁 至 70 岁(登记的条件)
牵头:华中科技大学同济医学院附属协和医院武汉
- 即将招募Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
- 分期
- III期
- 开始
- 2025-09
- 登记号
- NCT06580223
年龄 18 岁 至 90 岁(登记的条件)
牵头:华中科技大学同济医学院附属协和医院武汉
- 正在招募A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- 分期
- I期
- 开始
- 2026-05
- 登记号
- NCT07477587
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛
- 正在招募LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
- 分期
- 不分期
- 开始
- 2025-09
- 登记号
- NCT07100067
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、天津、武汉
- 正在招募A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
- 分期
- III期
- 开始
- 2024-06
- 登记号
- NCT06508983
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、天津、广州、杭州、武汉、苏州、西安、郑州
- 正在招募A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
- 分期
- I/II期
- 开始
- 2023-10
- 登记号
- NCT06049290
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、厦门、太原、宁波、广州、杭州、武汉、沈阳、海口、深圳、温州、苏州、西安、贵阳、郑州、长春、青岛
- 正在招募OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
- 分期
- I/II期
- 开始
- 2023-10
- 登记号
- NCT06182696
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、北京、南京、杭州、武汉
- 正在招募A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- 分期
- I/II期
- 开始
- 2021-09
- 登记号
- NCT04973605
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南京、南昌、厦门、天津、杭州、武汉、沈阳、石家庄、福州、郑州、重庆、长沙、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文30
- Global burden of multiple myeloma in older adults from 1990 to 2021 and modeled projection to 2050.
- Targeted Delivery of c(RGDfk)-Modified Liposomes to Bone Marrow Through In Vivo Hitchhiking Neutrophils for Multiple Myeloma Therapy.
- Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis.
- Integrating single-cell and bulk RNA profiles to uncover glutamine metabolism's role in prognosis and immune dynamics in multiple myeloma.
- Macrophage migration inhibitory factor as a prognostic biomarker in multiple myeloma: clinical significance and in vitro effects.
- ZNF655 involved in the progression of multiple myeloma via the activation of AKT.
- Polymerase theta inhibition impairs tumor growth and amplifies melphalan-induced DNA damage in multiple myeloma.
- ALKHB5-demethylated lncRNA SNHG15 promotes myeloma tumorigenicity by increasing chromatin accessibility and recruiting H3K36me3 modifier SETD2.
- Circulating plasma cells as a predictive biomarker in Multiple myeloma: an updated systematic review and meta-analysis.
- Class II ferroptosis inducers are a novel therapeutic approach for t(4;14)-positive multiple myeloma.
- Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy.
- Different evasion strategies in multiple myeloma.
- GLYR1 transcriptionally regulates PER3 expression to promote the proliferation and migration of multiple myeloma.
- Development of a nomogram prognostic model for early Grade ≥ 3 infection in newly diagnosed multiple myeloma based on immunoparesis.
- Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma.
- Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?
- Hematologists' awareness of venous thromboembolism in multiple myeloma: a national survey in China.
- Multiple immunoglobulin isotype switch after bispecific CAR-T cell therapy in multiple myeloma-A case report.
- MALAT1 regulates network of microRNA-15a/16-VEGFA to promote tumorigenesis and angiogenesis in multiple myeloma.
- ACSL4: a double-edged sword target in multiple myeloma, promotes cell proliferation and sensitizes cell to ferroptosis.
- CCL18 promotes migration and invasion of multiple myeloma cells and is associated with poor prognosis.
- A prognostication system based on clinical parameters and [18F]-FDG PET/CT in patients with newly diagnosed multiple myeloma.
- The risk factors for coagulation disorder of chimeric antigen receptor-T cell therapy in patients with hematological tumors: A systematic review and meta-analysis.
- Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma.
- ALKBH5 Promotes Multiple Myeloma Tumorigenicity through inducing m6A-demethylation of SAV1 mRNA and Myeloma Stem Cell Phenotype.
- FTO promotes multiple myeloma progression by posttranscriptional activation of HSF1 in an m6A-YTHDF2-dependent manner.
- Prognostic nomogram incorporating cytokines for overall survival in patients with newly diagnosed multiple myeloma.
- A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
- JunB is a key regulator of multiple myeloma bone marrow angiogenesis.
- COVID-19 in patients with multiple myeloma: a cross-sectional survey from the most severely affected region in China.
中文论文(未计入)5
- [Development, reliability, and validity of a treatment-related quality of life scale for Chinese patients with multiple myeloma].
- [BCMA/CS1 bispecific CAR-T cell therapy for multiple myeloma complicated with thrombocytopenia: a case report and literature review].
- [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
- [Update on biology of primary plasma cell leukemia].
- [Clinical characteristics of patients with multiple myeloma harboring 6q deletion].
它在 ClinicalTrials.gov 上的全部试验(任何状态)29
- A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.
- Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
- An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
- The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial
- Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
- Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM
- A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.
- A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy
- Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies
- T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
- A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
- A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
- OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
- A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma
- ATG-010(Selinexor) in Combination With Chemotherapy in RRMM
- Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma
- APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma
- Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma
- Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
- A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
- A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
- Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
- Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)
血液疾病
B 细胞急性淋巴细胞白血病
B-cell acute lymphoblastic leukaemia2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.3%。
武汉有 3 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下
这家医院参与的开放试验 9
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults
- 分期
- 早期I期
- 开始
- 2026-04
- 登记号
- NCT07470073
年龄 12 岁 至 75 岁(登记的条件)
牵头:华中科技大学同济医学院附属协和医院武汉
- 正在招募CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
- 分期
- I/II期
- 开始
- 2024-11
- 登记号
- NCT06735495
年龄 3 岁 至 75 岁(登记的条件)
牵头:华中科技大学同济医学院附属协和医院武汉
- 正在招募Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
- 分期
- II/III期
- 开始
- 2025-01
- 登记号
- NCT06764238
年龄 1 个月 至 18 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所);另有 24 家列出的医院为研究中心上海、南京、南宁、南昌、合肥、天津、广州、成都、武汉、济南、深圳、福州、苏州、西安、贵阳、重庆、长沙、青岛
- 正在招募Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
- 分期
- II/III期
- 开始
- 2025-03
- 登记号
- NCT06882057
年龄 1 岁 至 18 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所);另有 23 家列出的医院为研究中心上海、南京、南宁、南昌、合肥、天津、广州、成都、武汉、济南、福州、苏州、西安、贵阳、重庆、长沙、青岛
- 正在招募Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
- 分期
- III期
- 开始
- 2025-03
- 登记号
- NCT07152041
年龄 1 个月 至 18 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所);另有 20 家列出的医院为研究中心上海、南京、南昌、天津、广州、成都、武汉、济南、深圳、福州、苏州、贵阳、重庆、长沙、青岛
- 正在招募The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia
- 分期
- 早期I期
- 开始
- 2024-03
- 登记号
- NCT06307600
年龄 3 岁 至 70 岁(登记的条件)
牵头:中国科学技术大学附属第一医院(安徽省立医院);另有 1 家列出的医院为研究中心合肥、武汉
- 正在招募Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
- 分期
- 未注明
- 开始
- 2024-06
- 登记号
- NCT06450067
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、天津、广州、徐州、成都、武汉、济南、郑州
- 正在招募A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
- 分期
- I/II期
- 开始
- 2023-02
- 登记号
- NCT05667506
年龄 3 岁 至 18 岁(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心南京、南昌、合肥、天津、广州、徐州、武汉、重庆
- 正在招募A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
- 分期
- I/II期
- 开始
- 2022-11
- 登记号
- NCT05579132
年龄 2 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心天津、广州、徐州、成都、杭州、武汉、郑州、重庆
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文3
- Novel Prognostic Scoring Systems for Severe CRS after Anti-CD19 CAR-T-Cells in Acute B-Lymphoblastic Leukemia.
- Biomarkers for predicting CAR-T cell therapy outcomes in B-cell acute lymphoblastic leukemia: a systematic review.
- Bone marrow blasts- and modified EASIX-guided risk stratification for coagulopathy and outcomes after CAR-T therapy in relapsed/refractory B-ALL.
中文论文(未计入)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)19
- A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults
- CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
- CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors
- Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies
- Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies
- Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies
- Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies
- Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
- Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
- Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
- Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
- The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia
- A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
- A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
- A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
- Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
- Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies
- Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies
- CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
血液疾病
再生障碍性贫血
Aplastic anaemia2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
武汉有 4 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 即将招募Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin
- 分期
- 不分期
- 开始
- 2026-05
- 登记号
- NCT07552506
年龄 14 岁 至 50 岁;仅女性(登记的条件)
牵头:华中科技大学同济医学院附属协和医院;另有 3 家列出的医院为研究中心杭州、武汉、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文2
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
血液疾病
噬血细胞性淋巴组织细胞增生症
Haemophagocytic lymphohistiocytosis2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 8 篇,占 2.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
武汉有 2 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
- 分期
- III期
- 开始
- 2025-11
- 登记号
- NCT07208058
年龄 16 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南昌、广州、杭州、武汉、沈阳、石家庄、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文8
- Development and validation of a predictive model for diagnosing EBER-positive lymphoma-associated hemophagocytic lymphohistiocytosis.
- C3 as a predictive and prognostic biomarker in adult hemophagocytic lymphohistiocytosis: a large cohort study in China.
- Hemophagocytic lymphohistiocytosis post chimeric antigen receptor T cell therapies.
- Ruxolitinib-loaded cytokine nanosponge alleviated the cytokine storm and dampened macrophage overactivation for the treatment of hemophagocytic lymphohistiocytosis.
- Clinical utility of plasma Epstein-Barr virus DNA monitoring in pediatric Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: a Chinese retrospective observational study.
- Clinical significance and different strategies for re-elevation of plasma EBV-DNA during treatment in pediatric EBV-associated hemophagocytic lymphohistiocytosis.
- Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis complicated by neurological involvement in a patient with dermatomyositis: A case report and literature review.
- Hemophagocytic lymphohistiocytosis after COVID-19 vaccination.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
PubMed 以外找到的论文(未计入)3
- CLAMP: A phase II prospective study of camrelizumab combined with pegaspargase, etoposide, and high-dose methotrexate in patients with natural killer (NK)/T-cell lymphoma.
- Clinical features and prognostic factors of adult patients with hemophagocytic lymphohistiocytosis: a retrospective study of 130 adult patients
- Pattern and Prognosis of Distant Metastases in Patients with Early-Stage Extranodal Nasal-Type NK/T-Cell Lymphoma
血液疾病
血友病 A
Haemophilia A2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
武汉有 2 家医院列在血友病 A下全国有 160 家医院列在血友病 A下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
- 分期
- III期
- 开始
- 2025-03
- 登记号
- NCT06833983
年龄 18 岁 至 65 岁;仅男性(登记的条件)
牵头方不是列出的医院;另有 13 家列出的医院为研究中心兰州、北京、南京、南昌、合肥、唐山、天津、广州、昆明、武汉、济南、郑州、长沙
- 正在招募Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
- 分期
- II/III期
- 开始
- 2024-01
- 登记号
- NCT06111638
年龄 18 岁 至 未注明;仅男性(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心Xi’an、北京、天津、广州、成都、昆明、武汉、苏州、贵阳、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文1
早期论文(2016–2020 年)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
- To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
- Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
- Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.
- Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
- A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A
- To Evaluate the Safety and Efficacy of GS1191-0445 Injection in the Treatment of Severe Hemophilia A
- China ADVATE PTP Study
血液疾病
范可尼贫血
Fanconi anaemia2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
武汉有 2 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。
其他疾病
视神经脊髓炎谱系疾病
Neuromyelitis optica spectrum disorder2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
武汉有 2 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的视神经脊髓炎谱系疾病开放试验。
其他疾病
IgG4相关性疾病
IgG4-related disease2021–2025 年没有牵头IgG4相关性疾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
武汉有 2 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的IgG4相关性疾病开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
PubMed 以外找到的论文(未计入)1
其他疾病
重症肌无力
Myasthenia gravis武汉有 3 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
- 分期
- 不分期
- 开始
- 2026-03
- 登记号
- NCT07470151
年龄 18 岁 至 70 岁(登记的条件)
牵头:华中科技大学同济医学院附属协和医院武汉
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
- Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
- A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases
- A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
- Study of Telitacicept in Generalized Myasthenia Gravis
其他疾病
烟雾病
Moyamoya disease2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
武汉有 3 家医院列在烟雾病下全国有 47 家医院列在烟雾病下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的烟雾病开放试验。
这些数字背后的记录
牵头的论文2
其他疾病
胆道闭锁
Biliary atresia2021–2025 年中国大陆作者发表的 214 篇胆道闭锁 PubMed 英文论文中,这家医院牵头了 7 篇,占 3.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
武汉有 2 家医院列在胆道闭锁下全国有 28 家医院列在胆道闭锁下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的胆道闭锁开放试验。
这些数字背后的记录
牵头的论文7
- Biliary atresia: Rotavirus amplification of lipopolysaccharide/toll-like receptor 4 by mediating MMP7 upregulation through NF-κB.
- Identification and validation of oxidative stress-related genes in biliary atresia.
- Comparison of surgical results and technical performance between robotic and laparoscopic approaches for Kasai portoenterostomy in biliary atresia: a multicenter retrospective study.
- Comparison between robotic-assisted Kasai portoenterostomy and open Kasai portoenterostomy in patients with biliary atresia.
- Inhibition of Notch3/Hey1 ameliorates peribiliary hypoxia by preventing hypertrophic hepatic arteriopathy in biliary atresia progression.
- Robotic-assisted Kasai portoenterostomy for biliary atresia.
- Dynamic analysis of serum MMP-7 and its relationship with disease progression in biliary atresia: a multicenter prospective study.
其他疾病
抗 NMDA 受体脑炎
Anti-NMDA receptor encephalitis2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
武汉有 5 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。
其他疾病
大动脉炎
Takayasu arteritis2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
武汉有 4 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
武汉有 9 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- 分期
- III期
- 开始
- 2026-09
- 登记号
- NCT07687459
年龄 40 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 45 家列出的医院为研究中心Yuncheng、上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、郑州、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文3
- Pre-exposure to Aerosolized Polyvalent Bacterial Lysates Protects Against Bleomycin-Induced Pulmonary Fibrosis in Mice.
- Pleural mesothelial cell migration into lung parenchyma by calpain contributes to idiopathic pulmonary fibrosis.
- VEGF/Src signaling mediated pleural barrier damage and increased permeability contributes to subpleural pulmonary fibrosis.
早期论文(2016–2020 年)3
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
其他疾病
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025 年没有牵头肌萎缩侧索硬化症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
武汉有 6 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。
这些数字背后的记录
其他疾病
白塞病
Behçet disease2021–2025 年没有牵头白塞病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
武汉有 7 家医院列在白塞病下全国有 149 家医院列在白塞病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
武汉有 8 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of YKST02 in Participants With Primary IgA Nephropathy
- 分期
- 早期I期
- 开始
- 2026-05
- 登记号
- NCT07498673
年龄 18 岁 至 75 岁(登记的条件)
牵头:华中科技大学同济医学院附属协和医院武汉
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文2
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
其他疾病
成骨不全症
Osteogenesis imperfecta2021–2025 年中国大陆作者发表的 99 篇成骨不全症 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
武汉有 2 家医院列在成骨不全症下全国有 59 家医院列在成骨不全症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。
其他疾病
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
武汉有 5 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- 分期
- III期
- 开始
- 2023-09
- 登记号
- NCT06051617
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、乌鲁木齐、北京、合肥、广州、成都、杭州、武汉、福州、西安、贵阳、郑州、重庆、长春
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文3
- A Phenome-Wide Mendelian Randomization and Colocalization Study Reveals Genetic Association Between PBC and Other Autoimmune Disorders.
- Prevalence and impact of Sjögren's syndrome in primary biliary cholangitis: a systematic review and meta-analysis.
- The HSP90 inhibitor 17-DMAG alleviates primary biliary cholangitis via cholangiocyte necroptosis prevention.
早期论文(2016–2020 年)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
其他疾病
原发性硬化性胆管炎
Primary sclerosing cholangitis2021–2025 年没有牵头原发性硬化性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
武汉有 3 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。
这些数字背后的记录
早期论文(2016–2020 年)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
先天性膈疝
Congenital diaphragmatic hernia2021–2025 年中国大陆作者发表的 60 篇先天性膈疝 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
武汉有 1 家医院列在先天性膈疝下全国有 46 家医院列在先天性膈疝下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性膈疝开放试验。
其他疾病
先天性巨结肠
Hirschsprung disease2021–2025 年中国大陆作者发表的 161 篇先天性巨结肠 PubMed 英文论文中,这家医院牵头了 8 篇,占 5.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
武汉有 3 家医院列在先天性巨结肠下全国有 82 家医院列在先天性巨结肠下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。
这些数字背后的记录
牵头的论文8
- Tight junction dysfunction and cytoskeletal remodeling in Hirschsprung‑associated enterocolitis: A decade of mechanistic insights and therapeutic prospects (Review).
- Robotic-assisted Proctosigmoidectomy Versus Laparoscopic-assisted Soave Pull-through for Hirschsprung Disease: Medium-term Outcomes From a Prospective Multicenter Study.
- Whole-genome sequencing identified ALK as a novel susceptible gene of Hirschsprung disease.
- Secretagogin Downregulation Impairs Nerve Cell Migration in Hirschsprung Disease via Inhibition of the LEF-1/NCAM1 Axis.
- Update on the Pathogenesis of the Hirschsprung-Associated Enterocolitis.
- Robotic-assisted proctosigmoidectomy for Hirschsprung's disease: A multicenter prospective study.
- Hirschsprung's disease: key microRNAs and target genes.
- Skip segment Hirschsprung's disease: diagnostic clues and surgical management.
早期论文(2016–2020 年)12
- Resuturing Without Enterostomy for the Treatment of Early-Stage Anastomotic Leaks After Laparoscopic Soave Procedure in Hirschsprung's Disease.
- Primary laparoscopic endorectal pull-through procedure with or without a postoperative rectal tube for hirschsprung disease: a multicenter perspective study.
- Laparoscopic Redo Pull-Through for Hirschsprung Disease Due to Innervation Disorders.
- Increased miR-214 expression suppresses cell migration and proliferation in Hirschsprung disease by interacting with PLAGL2.
- Transumbilical enterostomy for Hirschsprung's disease with a two-stage laparoscopy-assisted pull-through procedure.
- Duhamel operation vs. transanal endorectal pull-through procedure for Hirschsprung disease: A systematic review and meta-analysis.
- Laparoscopic-assisted Duhamel procedure with ex-anal rectal transection for total colonic aganglionosis.
- Gli family zinc finger 1 is associated with endothelin receptor type B in Hirschsprung disease.
- Laparoscopic Duhamel Procedure with Ex-Anal Rectal Transection for Right-Sided Hirschsprung's Disease.
- Neuregulin 1 is involved in enteric nervous system development in zebrafish.
- Effects of NRG1 Polymorphisms on Hirschsprung's Disease Susceptibility: A Meta-analysis.
- Effects of RET, NRG1 and NRG3 Polymorphisms in a Chinese Population with Hirschsprung Disease.
其他疾病
家族性腺瘤性息肉病
Familial adenomatous polyposis2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
武汉有 4 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。
这些数字背后的记录
早期论文(2016–2020 年)2
- Ex vivo resection and intestinal autotransplantation for a large mesenteric desmoid tumor secondary to familial adenomatous polyposis: A case report and literature review.
- ALK-positive gastric inflammatory myofibroblastic tumor in an adult with familial adenomatous polyposis and diffuse fundic polyposis.
联系这家医院
出示给工作人员或司机的院名卡
华中科技大学同济医学院附属协和医院
Union Hospital
武汉
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。
编号与其他名称
ROR Wikidata
Wuhan Union Hospital; Union Hospital of Tongji Medical College; Huazhong University of Science and Technology; Union Hospital Tongji Medical College; Union Hospital Wuhan; Union Hospital of Huazhong University of Science and Technology; Union Hospital Affiliated to Tongji Medical College; Tongji Medical College Union Hospital